Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile
- PMID: 3349495
Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile
Abstract
The occurrence of tamoxifen metabolites in bile was investigated in a 57-year-old female patient receiving chronic treatment with tamoxifen. In bile treated with beta-glucuronidase, two major peaks were detected using a chromatographic system developed for the quantitation of tamoxifen metabolites in human serum. One sharp peak coeluted with 4-hydroxy-tamoxifen whereas a second broad peak eluted slightly ahead of tamoxifen and was separated from all major serum metabolites. This latter peak was identified as the cis (about 30%) and trans (about 70%) isomers of 4-hydroxy-N-desmethyltamoxifen. The identification was based on (a) coelution with authentic standard on reversed-phase chromatography and formation of fluorescent material after photoactivation, (b) a molecular ion (M + 1)+ of 374 m/z as determined with liquid chromatography-mass spectrometry, and (c) a fragmentogram identical to that of the authentic standard, as obtained by gas chromatography-mass spectrometry.
Similar articles
-
Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment.Cancer Res. 1989 Apr 15;49(8):2175-83. Cancer Res. 1989. PMID: 2702659
-
Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients.Drug Metab Dispos. 1993 Nov-Dec;21(6):1119-24. Drug Metab Dispos. 1993. PMID: 7905393
-
Excretion of hydroxylated metabolites of tamoxifen in human bile and urine.Anticancer Res. 2005 Nov-Dec;25(6C):4487-92. Anticancer Res. 2005. PMID: 16334131
-
Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques.J Pharm Biomed Anal. 2011 Jun 1;55(3):518-26. doi: 10.1016/j.jpba.2011.02.009. Epub 2011 Feb 18. J Pharm Biomed Anal. 2011. PMID: 21392921 Review.
-
Identification of metabolism pathways of anticancer drugs by high-pressure liquid chromatography in combination with field desorption mass spectrometry.Arzneimittelforschung. 1982;32(9):995-1012. Arzneimittelforschung. 1982. PMID: 6756419 Review.
Cited by
-
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen.Ann N Y Acad Sci. 2009 Feb;1155:99-111. doi: 10.1111/j.1749-6632.2009.04114.x. Ann N Y Acad Sci. 2009. PMID: 19250197 Free PMC article. Review.
-
Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants.Breast Cancer Res. 2006;8(4):R50. doi: 10.1186/bcr1539. Breast Cancer Res. 2006. PMID: 16884532 Free PMC article.
-
Germline pharmacogenetics of tamoxifen response: have we learned enough?J Clin Oncol. 2007 Nov 20;25(33):5147-9. doi: 10.1200/JCO.2007.13.4957. J Clin Oncol. 2007. PMID: 18024859 Free PMC article. No abstract available.
-
Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.Expert Rev Clin Pharmacol. 2011 May;4(3):363-77. doi: 10.1586/ecp.11.18. Expert Rev Clin Pharmacol. 2011. PMID: 21709817 Free PMC article. Review.
-
High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines.Br J Cancer. 1992 Nov;66(5):833-9. doi: 10.1038/bjc.1992.369. Br J Cancer. 1992. PMID: 1358168 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources